FindTrial
Sign In

A pilot clinical trial to evaluate the ability of pegylate r-metHg-CSF (Pegilgrastim) to accelerate haematology recovery of patients with Non-Hodgkins Lymphoma after High-dose chemiotherapy and autologous stem cell transplantation.

A pilot clinical trial to evaluate the ability of pegylate r-metHg-CSF (Pegilgrastim) to accelerate haematology recovery of patients with Non-Hodgkins Lymphoma after High-dose chemiotherapy and autologous stem cell transplantation.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-004442-14-IT
Enrollment
Unknown
Registered
2005-11-22
Start date
2005-12-06
Completion date
Unknown
Last updated
2012-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with - risk Non-Hodgkin's Lymphoma in complete or partial response who underwent autologous PBPC transplantation after high-dose chemiotherapy. MedDRA version: 6.1 Level: HLT Classification code 10012819

Interventions

Trade Name: NEULASTA*6MG SC 1 SIR. Pharmaceutical Form: Solution for injection INN or Proposed INN: Pegfilgrastim Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6-

Sponsors

UNIVERSITA' DEGLI STUDI DI UDINE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026